Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Autologous Stem Cell Transplant Has a Role In Consolidating Chemotherapy Given At First Disease Progression In Multiple Myeloma Treated Exclusively With Novel Agents

Blood (2013) 122 (21): 5514.

https://doi.org/10.1182/blood.V122.21.5514.5514

Published: 2013

Journal Articles

R-CHOP Alone For Rituximab Naive Transformed Follicuar Lymphoma Has An Excellent Outcome

Y L Tracey Chan, Bindu Vydianath, Charlotte F Inman, Prem Mahendra, Ram Malladi, Sridhar Chaganti

Blood (2013) 122 (21): 4392.

https://doi.org/10.1182/blood.V122.21.4392.4392

Published: 2013

Journal Articles

Outcomes of Eam Conditioned Autologous Haematopoietic Stem Cell Transplantation for Lymphoma. A Matched Pairs Retrospective Single Centre Study Analysis.

Justin Ching Ting Loke, BM BCh, Janice Ward, Prem Mahendra, Sridhar Chaganti, Ram Malladi

Blood (2012) 120 (21): 3088.

https://doi.org/10.1182/blood.V120.21.3088.3088

Published: 2012

Journal Articles

Pre-Transplant Rituximab Is Associated with a Greatly Reduced Risk of Epstein-Barr Virus Reactivation Following Allogeneic Stem Cell Transplantation

David Burns, Shabeeha Rana, Andrew Howman, Sandeep Nagra, Janice Ward, Husam Osman, Yusri Taha, Jenny Byrne, Emma Das-Gupta, Manoj Raghavan, Ram Malladi, Mark Cook, Prem Mahendra, Nigel H. Russell, MD, Charles Craddock, Christopher Fox, Sridhar Chaganti

Blood (2012) 120 (21): 460.

https://doi.org/10.1182/blood.V120.21.460.460

Published: 2012

Journal Articles

Chemokine-mediated tissue recruitment of CXCR3 + CD4 + T cells plays a major role in the pathogenesis of chronic GVHD

Joanne E. Croudace, Charlotte F. Inman, Ben. E. Abbotts, Sandeep Nagra, Jane Nunnick, Prem Mahendra, Charles Craddock, Ram Malladi, Paul A. H. Moss

Blood (2012) 120 (20): 4246–4255.

https://doi.org/10.1182/blood-2012-02-413260

Published: 2012

Includes: Supplemental data

Journal Articles

Pre-Emptive Rituximab for Epstein-Barr Virus Reactivation Post Stem Cell Transplant: High CRP and PTLD At Initiation of Treatment Confer Inferior Outcome

David Burns, Sandeep Nagra, Husam Osman, Ram Malladi, Manoj Raghavan, Fiona Clark, Mark Cook, Prem Mahendra, Charles Craddock, Sridhar Chaganti

Blood (2011) 118 (21): 3007.

https://doi.org/10.1182/blood.V118.21.3007.3007

Published: 2011

Journal Articles

Pretransplant Characteristics Could Predict Full Donor Chimerism on Day +90 and Day +180 and Outcomes in Reduced Intensity Alemtuzumab Conditioning Allogeneic Transplantation Can Be Influenced by Chimeric Status

Emmanouil Nikolousis, Charles F. Craddock, BM, MRCP, MRCPath, Shankaranarayana Paneesha, MD, Sudhir Tauro, Prem Mahendra, II, Mark Cook, Fiona Clark, Richard Lovell, Sridhar Chaganti, Donald Milligan, MD, MBChB, Dominique Mcmullan, Mike Griffiths, Stephen P Robinson, MD

Blood (2008) 112 (11): 4409.

https://doi.org/10.1182/blood.V112.11.4409.4409

Published: 2008

Journal Articles

Cyclosporine dose Intensity Is a Critical Determinant of Outcome after a T Cell Depleted Reduced Intensity Allograft.

Charles F. Craddock, BM, MRCP, MRCPath, Sandeep Nagra, Cassandra Brookes, Nick Duncan, Alison H Thomson, Prem Mahendra, Janice Ward, Fiona Clark, Paul Moss, Mark Cook

Blood (2008) 112 (11): 1153.

https://doi.org/10.1182/blood.V112.11.1153.1153

Published: 2008

Journal Articles

A Randomised, Double-Blind, Placebo Controlled, Multicentre Trial of ATL-104, a Swallowable Mouthwash, in Patients with Oral Mucositis Following Peripheral Blood Stem Cell Transplantion (PBSCT).

Ann Hunter, FRCP, FRCPath, Prem Mahendra, FRCP FRCPath, Keith Wilson, FRCP FRCPath, Paul Fields, PhD FRCP FRCPath, Gordon Cook, PhD FRCP FRCPath, Andrew Peniket, FRCP FRCPath, Charles Crawley, FRCP FRCPath, Rob Hallam, PhD FICR, Roger Hickling, BSc, Richard Palmer, PhD, Robert Marcus, FRCP, FRCPath

Blood (2006) 108 (11): 45.

https://doi.org/10.1182/blood.V108.11.45.45

Published: 2006

Journal Articles

Cancer Germline Antigen-Specific T Cells Are Present and Functional in Many Patients with Multiple Myeloma and Paraproteinaemia.

Oliver Goodyear, PhD, Karen Piper, PhD, Naeem Khan, PhD, Jane Starczynski, PhD, Prem Mahendra, MD, Guy Pratt, MD, Paul Moss, PhD

Blood (2006) 108 (11): 3507.

https://doi.org/10.1182/blood.V108.11.3507.3507

Published: 2006

Journal Articles

CD8 + T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden

Oliver Goodyear, Karen Piper, Naeem Khan, Jane Starczynski, Prem Mahendra, Guy Pratt, Paul Moss

Blood (2005) 106 (13): 4217–4224.

https://doi.org/10.1182/blood-2005-02-0563

Published: 2005

Includes: Supplemental data

Journal Articles

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

Emma Morris, Kirsty Thomson, Charles Craddock, Prem Mahendra, Donald Milligan, Gordon Cook, Graeme Murray Smith, Anne Parker, Steve Schey, Rajesh Chopra, Christopher Hatton, Jane Tighe, Anne Hunter, Karl Peggs, David Linch, Anthony Goldstone, Stephen Mackinnon

Blood (2004) 104 (13): 3865–3871.

https://doi.org/10.1182/blood-2004-03-1105

Published: 2004

Journal Articles

Direct Adoptive Transfer of Cytomegalovirus-Specific CTL from Unrelated Donors to Stem Cell Transplant Patients Following Selection by HLA-Peptide Tetramers.

Mark Cobbold, MD, PhD, Persis Amrolia, MD, PhD, Prem Mahendra, MD, PhD, Colin Steward, MD, PhD, Eduardo Olavarria, MD, PhD, Julie Arrazi, Dorothy McDonald, PhD, Sudhir Tauro, MD, PhD, John Goldman, MD, PhD, Charles Craddock, MD, PhD, Paul Moss, MD, PhD

Blood (2004) 104 (11): 155.

https://doi.org/10.1182/blood.V104.11.155.155

Published: 2004

Journal Articles

The Relationship between Host Antigen-Presenting Cells and Graft-versus-Host Responses Following Human Nonmyeloablative Transplantation.

Fiona J. Clark, Mike Griffiths, Matt Collin, Prem Mahendra, Charles Craddock, Graham Jackson, Don Milligan, Paul A. Moss, Ronjon Chakraverty

Blood (2004) 104 (11): 2252.

https://doi.org/10.1182/blood.V104.11.2252.2252

Published: 2004

Journal Articles

BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients

Rowena D. Faulkner, Charles Craddock, Jennifer L. Byrne, Prem Mahendra, Andrew P. Haynes, Hugh G. Prentice, Michael Potter, Antonio Pagliuca, Aloysius Ho, Stephen Devereux, Grant McQuaker, Ghulam Mufti, John Liu Yin, Nigel H. Russell

Blood (2004) 103 (2): 428–434.

https://doi.org/10.1182/blood-2003-05-1406

Published: 2004

Journal Articles

Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma

Victoria J. Spanswick, Charles Craddock, Mallika Sekhar, Prem Mahendra, Paneesha Shankaranarayana, R. George Hughes, Daniel Hochhauser, John A. Hartley

Blood (2002) 100 (1): 224–229.

https://doi.org/10.1182/blood.V100.1.224

Published: 2002

Journal Articles

Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation

Kate Cwynarski, Jenni Ainsworth, Mark Cobbold, Simon Wagner, Prem Mahendra, Jane Apperley, John Goldman, Charles Craddock, Paul A. H. Moss

Blood (2001) 97 (5): 1232–1240.

https://doi.org/10.1182/blood.V97.5.1232

Published: 2001

NARROW

Autologous Stem Cell Transplant Has a Role In Consolidating Chemotherapy Given At First Disease Progression In Multiple Myeloma Treated Exclusively With Novel Agents

R-CHOP Alone For Rituximab Naive Transformed Follicuar Lymphoma Has An Excellent Outcome

Outcomes of Eam Conditioned Autologous Haematopoietic Stem Cell Transplantation for Lymphoma. A Matched Pairs Retrospective Single Centre Study Analysis.

Pre-Transplant Rituximab Is Associated with a Greatly Reduced Risk of Epstein-Barr Virus Reactivation Following Allogeneic Stem Cell Transplantation

Chemokine-mediated tissue recruitment of CXCR3 + CD4 + T cells plays a major role in the pathogenesis of chronic GVHD

Pre-Emptive Rituximab for Epstein-Barr Virus Reactivation Post Stem Cell Transplant: High CRP and PTLD At Initiation of Treatment Confer Inferior Outcome

Pretransplant Characteristics Could Predict Full Donor Chimerism on Day +90 and Day +180 and Outcomes in Reduced Intensity Alemtuzumab Conditioning Allogeneic Transplantation Can Be Influenced by Chimeric Status

Cyclosporine dose Intensity Is a Critical Determinant of Outcome after a T Cell Depleted Reduced Intensity Allograft.

A Randomised, Double-Blind, Placebo Controlled, Multicentre Trial of ATL-104, a Swallowable Mouthwash, in Patients with Oral Mucositis Following Peripheral Blood Stem Cell Transplantion (PBSCT).

Cancer Germline Antigen-Specific T Cells Are Present and Functional in Many Patients with Multiple Myeloma and Paraproteinaemia.

CD8 + T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

Direct Adoptive Transfer of Cytomegalovirus-Specific CTL from Unrelated Donors to Stem Cell Transplant Patients Following Selection by HLA-Peptide Tetramers.

The Relationship between Host Antigen-Presenting Cells and Graft-versus-Host Responses Following Human Nonmyeloablative Transplantation.

BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients

Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma

Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only